Pieris Pharmaceuticals Inc (NASDAQ: PIRS)’s stock price has gone decline by -7.36 in comparison to its previous close of 0.25, however, the company has experienced a -16.30% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-09-25 that Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Pieris Pharmaceuticals Inc (NASDAQ: PIRS) Right Now?
, and the 36-month beta value for PIRS is at 0.73. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price suggested by analysts for PIRS is $7.00, which is $6.77 above the current market price. The public float for PIRS is 86.55M, and currently, shorts hold a 0.21% of that float. The average trading volume for PIRS on November 16, 2023 was 1.67M shares.
PIRS’s Market Performance
The stock of Pieris Pharmaceuticals Inc (PIRS) has seen a -16.30% decrease in the past week, with a -14.85% drop in the past month, and a -10.92% fall in the past quarter. The volatility ratio for the week is 9.54%, and the volatility levels for the past 30 days are at 7.78% for PIRS. The simple moving average for the past 20 days is -7.74% for PIRS’s stock, with a -65.89% simple moving average for the past 200 days.
Analysts’ Opinion of PIRS
Many brokerage firms have already submitted their reports for PIRS stocks, with Robert W. Baird repeating the rating for PIRS by listing it as a “Outperform.” The predicted price for PIRS in the upcoming period, according to Robert W. Baird is $5 based on the research report published on March 13, 2020 of the previous year 2020.
PIRS Trading at -18.77% from the 50-Day Moving Average
After a stumble in the market that brought PIRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.24% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 9.54%, as shares sank -12.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.35% lower at present.
During the last 5 trading sessions, PIRS fell by -16.30%, which changed the moving average for the period of 200-days by -85.53% in comparison to the 20-day moving average, which settled at $0.2494. In addition, Pieris Pharmaceuticals Inc saw -77.73% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PIRS starting from KIRITSY CHRISTOPHER P, who purchase 10,000 shares at the price of $0.85 back on May 25. After this action, KIRITSY CHRISTOPHER P now owns 20,000 shares of Pieris Pharmaceuticals Inc, valued at $8,500 using the latest closing price.
Stock Fundamentals for PIRS
Current profitability levels for the company are sitting at:
- -167.84 for the present operating margin
- +89.27 for the gross margin
The net margin for Pieris Pharmaceuticals Inc stands at -128.47. The total capital return value is set at -81.51, while invested capital returns managed to touch -63.52. Equity return is now at value -84.68, with -35.40 for asset returns.
Based on Pieris Pharmaceuticals Inc (PIRS), the company’s capital structure generated 46.92 points at debt to equity in total, while total debt to capital is 31.93. Total debt to assets is 13.72, with long-term debt to equity ratio resting at 43.84. Finally, the long-term debt to capital ratio is 29.84.
When we switch over and look at the enterprise to sales, we see a ratio of -0.45, with the company’s debt to enterprise value settled at 0.42. The receivables turnover for the company is 5.68 and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.01.
In conclusion, Pieris Pharmaceuticals Inc (PIRS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.